AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie is launching an ambitious late-stage eye study called NAAVIGATE, formall...

AbbVie’s NAAVIGATE Trial Targets One-Time Gene Therapy for Diabetic Retinopathy

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CVS Health (CVS), BioMarin Pharmaceutical (BMRN) and...

Analysts Offer Insights on Healthcare Companies: CVS Health (CVS), BioMarin Pharmaceutical (BMRN) and AbbVie (ABBV)

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie’s new early stage study, officially titled “A Phase 1b Study to Assess t...

AbbVie Quietly Expands Its Obesity Bet With New ABBV-295 Trial

Abbvie ($ABBV) announced an update on their ongoing clinical study. The study, officially titled “An Open-label Extension of Study M15-741 to Evalu...

AbbVie’s ABBV-951 Parkinson’s Extension Study Completes, Setting Up Key Long-Term Safety Readout

An update from AbbVie ( ($ABBV) ) is now available. At AbbVie’s 2026 Annual Meeting of Stockholders held on May 8, 2026, shareholders elected four ...

AbbVie Shareholders Back Directors, Maintain Governance Structure

In a report released on May 8, Luisa Hector from Berenberg Bank maintained a Buy rating on AbbVie, with a price target of $275.00. The company’s sh...

AbbVie (ABBV) Receives a Buy from Berenberg Bank

AbbVie ( ($ABBV) ) has been popular among investors this week. Here is a recap of the key news on this stock. AbbVie has completed a Phase 1a trial...

AbbVie’s New Drug Milestone Fuels Hype Despite Insider Selling

Vanguard S&P 500 ETF ($VOO) remains one of the most popular choices for investors seeking broad exposure to the U.S. stock market. However, as mark...

Looking Beyond VOO? These 3 BlackRock ETFs Offer 20%+ Upside in 2026

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie (ABBV) has completed a Phase 1a study titled “A Phase 1a Study to Evalua...

AbbVie Completes Early Safety Study for ABBV-142, Nudging Pipeline Hopes Higher

BMO Capital analyst Evan Seigerman maintained a Buy rating on AbbVie today and set a price target of $258.00. According to TipRanks, Seigerman is a...

BMO Capital Sticks to Their Buy Rating for AbbVie (ABBV)

The article uses TipRanks’ Dividend Aristocrat tool to identify three dividend aristocrat stocks that have a Buy rating on Wall Street and hold at ...

3 Top Dividend Aristocrat Stocks That Could Hand Investors 15%+ Returns

Citi analyst Geoff Meacham maintained a Hold rating on AbbVie today and set a price target of $230.00. Meacham covers the Healthcare sector, focusi...

Citi Keeps Their Hold Rating on AbbVie (ABBV)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV), AxoGen (AXGN) and Niagen Bioscience (...

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), AxoGen (AXGN) and Niagen Bioscience (NAGE)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cartesian Therapeutics (RNAC), Cadrenal Therapeutics...

Analysts Are Bullish on Top Healthcare Stocks: Cartesian Therapeutics (RNAC), Cadrenal Therapeutics, Inc. (CVKD)

In a report released today, Gary Nachman from Canaccord Genuity reiterated a Buy rating on AbbVie, with a price target of $265.00. According to Tip...

Canaccord Genuity Sticks to Their Buy Rating for AbbVie (ABBV)

Here’s a quick look at today’s key earnings reports from major publicly traded companies. Investors will be watching closely for updates on financi...

Current Quarter	$3.77	Next Quarter	$3.88
Current Year	$14.3	Next Year	$16.3
QoQ Growth	+2.9%	YoY Growth	+14.0%
3Y EPS CAGR	-29.1%	Target Price	$250.90
Consensus	Buy	Upside	+17.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABBV	$214.40	-0.60%	1.21M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABBV	$214.40	-0.6%	1.21M
3
4
5
6

ABBV

ABBV

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get AbbVie Inc. Data in Excel

Get AbbVie Inc. Data in Excel